相关实验视频

Updated: Jul 24, 2025

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

莱纳利多米德耐药复发时间与新诊断的多发性骨髓瘤的预测者:第一个试验子分析

Salomon Manier¹, Meletios Dimopoulos², Cyrille Hulin³

¹Department of Hematology, Université de Lille, CHU Lille, Lille, France.

Clinical lymphoma, myeloma & leukemia

|July 1, 2023

概括

用莱纳利多米德和甲 (Rd) 治疗多发性骨髓瘤 (MM) 早期复发的患者面临较差的结果. 识别乳酸脱酶等预测因子可以指导高风险新诊断的MM (NDMM) 患者的强化治疗.

科学领域:

血液学血液学血液学
在瘤学瘤学.
临床试验临床试验

背景情况:

多发性骨髓瘤 (MM) 是一种无法治愈的血细胞恶性瘤,在初始治疗后复发的风险很高.
列纳利多米德与甲松 (Rd) 结合是一种新诊断的MM (NDMM) 的标准治疗方法,包括不符合干细胞移植条件的患者.
了解复发模式对于优化NDMM治疗策略至关重要.

研究的目的:

描述在Rd治疗中复发的移植不合格的NDMM患者,区分早期 (<12个月) 和晚期 (≥12个月) 复发.
确定预先预测Rd.治疗的NDMM患者早期复发的基线因素.
分析复发时间对患者结局的影响,包括无进展生存率 (PFS) 和整体生存率 (OS).

主要方法:

第三阶段FIRST试验数据的次分析.
卡普兰-梅尔方法用于估计时间到事件终点 (PFS,OS).
后勤回归 (单变量和多变量) 以确定早期和晚期复发的预测因素.

主要成果:

患有早期复发的患者与晚期复发的患者相比,结果明显差.
早期复发的中位数是26.8个月,而晚期复发的中位数是63.9个月.
乳酸脱酶,基线β2微球蛋白和髓瘤亚型被确定为复发时间的预测因素.

结论:

接受Rd治疗的NDMM患者的早期复发与高风险疾病和较差的存活率有关.
确定了预测因素,可以帮助临床医生分层对NDMM患者的风险.
这些信息可以指导为患有早期复发高风险的患者选择更积极的治疗方案.

关键词:

类动物类动物血液学血液学血液学没有NDMMM,没有NDMMM.这是一个很好的选择. Rd Rd 治疗策略治疗策略

更多相关视频

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

相关概念视频

Non-LTR Retrotransposons

Non-LTR Retrotransposons

As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...